It's entirely possible that we want better healthcare outcomes - all the historical trends point to that - but that we're more or less out of ideas how to get there on the cheap. This might be a new possibility.
In your model, why do we get improved, costlier insulin if the old thing was good enough? Because we actually want to pay more if it works better, and it doesn't mean we cut something else to make up for it. You just pay more in taxes in a subsidized model, or pay more at the pharmacy with private healthcare. There's a drug manufacturer profit motive in there, but it holds true in the added-cost ML scenario too.